ADVANCED ENZYME TECHNOLOGIES
Back to Balance Sheet
|
ADVANCED ENZYME TECHNOLOGIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹44 Cr | ₹49 Cr | ₹59 Cr | ₹49 Cr | ₹39 Cr |
What is the latest Total Non-Current Liabilities ratio of ADVANCED ENZYME TECHNOLOGIES ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹44 Cr |
Mar2023 | ₹49 Cr |
Mar2022 | ₹59 Cr |
Mar2021 | ₹49 Cr |
Mar2020 | ₹39 Cr |
How is Total Non-Current Liabilities of ADVANCED ENZYME TECHNOLOGIES Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹44 Cr | -10.30 | |
Mar2023 | ₹49 Cr | -17.87 | |
Mar2022 | ₹59 Cr | 20.87 | |
Mar2021 | ₹49 Cr | 26.91 | |
Mar2020 | ₹39 Cr | - |
Compare Total Non-Current Liabilities of peers of ADVANCED ENZYME TECHNOLOGIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
ADVANCED ENZYME TECHNOLOGIES | ₹3,207.1 Cr | -4.9% | -3.5% | -25.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹441,910.0 Cr | 5.4% | 3.2% | 20.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹160,035.0 Cr | 1.9% | 2% | 59.4% | Stock Analytics | |
CIPLA | ₹125,540.0 Cr | 1.7% | 2% | 13.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹112,894.0 Cr | 2.8% | 2.3% | 22.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹100,110.0 Cr | 2.1% | -0.9% | -1.5% | Stock Analytics |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ADVANCED ENZYME TECHNOLOGIES | -4.9% |
-3.5% |
-25.3% |
SENSEX | 1% |
4.3% |
8.9% |
You may also like the below Video Courses